Nashville, Tennessee 37232


Purpose:

This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors. 18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may show where tumor cells with estrogen receptors can be found in the body.


Study summary:

PRIMARY OBJECTIVES: I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC). OUTLINE: Patients undergo 18F-FES PET/CT imaging over 30 minutes. After completion of study, patients are followed up for 30 days.


Criteria:

Inclusion Criteria: - Patients with biopsy-proven extra-abdominal desmoid tumors - Not currently on estrogen medication for birth control, menopause, or other reason - No anti-estrogen therapy for desmoid tumor within the past 6 months - Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included Exclusion Criteria: - Pregnancy or nursing patients - Patients who do not wish to participate


NCT ID:

NCT02374931


Primary Contact:

Principal Investigator
Katherine Hartley, MD
Vanderbilt-Ingram Cancer Center

VICC Clinical Trials Information Program
Phone: 800-811-8480


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37232
United States

Katherine Hartley
Phone: 615-343-7185
Email: kate.hartley@vanderbilt.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.